Insider Selling: Inogen (INGN) Director Sells 1,000 Shares of Stock

Inogen (NASDAQ:INGN) Director Ray Benjamin M. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, April 17th. The stock was sold at an average price of $139.82, for a total value of $139,820.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $139,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Inogen stock opened at $141.08 on Friday. The firm has a market capitalization of $2,996.02, a PE ratio of 109.48, a PEG ratio of 3.93 and a beta of 1.03. Inogen has a fifty-two week low of $78.30 and a fifty-two week high of $144.05.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.10. The business had revenue of $63.79 million during the quarter, compared to analyst estimates of $62.01 million. Inogen had a return on equity of 13.47% and a net margin of 8.42%. analysts forecast that Inogen will post 1.6 EPS for the current year.

Several research analysts have recently issued reports on INGN shares. BidaskClub cut Inogen from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a research note on Tuesday, January 9th. Piper Jaffray raised Inogen from a “neutral” rating to an “overweight” rating in a research note on Tuesday, February 20th. Finally, Needham & Company LLC increased their price target on Inogen from $125.00 to $150.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, February 28th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $121.17.

Institutional investors have recently made changes to their positions in the company. Lenox Wealth Advisors Inc. acquired a new stake in shares of Inogen in the fourth quarter valued at $100,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Inogen by 1,000.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock valued at $130,000 after buying an additional 1,000 shares during the period. Simplex Trading LLC acquired a new stake in shares of Inogen in the fourth quarter valued at $153,000. LS Investment Advisors LLC lifted its holdings in shares of Inogen by 138.6% in the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock valued at $180,000 after buying an additional 880 shares during the period. Finally, Everence Capital Management Inc. acquired a new stake in shares of Inogen in the fourth quarter valued at $208,000. Institutional investors and hedge funds own 98.97% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Inogen (INGN) Director Sells 1,000 Shares of Stock” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.wkrb13.com/2018/04/21/insider-selling-inogen-ingn-director-sells-1000-shares-of-stock.html.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply